Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target

Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Peer Perform to Underperform and announces $9 price target.